Cargando…
The economic benefits of reducing cardiovascular disease mortality in Quebec, Canada
OBJECTIVES: We assess how different scenarios of cardiovascular disease (CVD) prevention, aimed at meeting targets set by the World Health Organization (WHO) for 2025), may impact healthcare spending in Quebec, Canada over the 2050 horizon. METHODS: We provide long-term forecasts of healthcare use a...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5754059/ https://www.ncbi.nlm.nih.gov/pubmed/29300783 http://dx.doi.org/10.1371/journal.pone.0190538 |
_version_ | 1783290361176653824 |
---|---|
author | Boisclair, David Décarie, Yann Laliberté-Auger, François Michaud, Pierre-Carl Vincent, Carole |
author_facet | Boisclair, David Décarie, Yann Laliberté-Auger, François Michaud, Pierre-Carl Vincent, Carole |
author_sort | Boisclair, David |
collection | PubMed |
description | OBJECTIVES: We assess how different scenarios of cardiovascular disease (CVD) prevention, aimed at meeting targets set by the World Health Organization (WHO) for 2025), may impact healthcare spending in Quebec, Canada over the 2050 horizon. METHODS: We provide long-term forecasts of healthcare use and costs at the Quebec population level using a novel dynamic microsimulation model. Using both survey and administrative data, we simulate the evolution of the Quebec population’s health status until death, through a series of dynamic transitions that accounts for social and demographic characteristics associated with CVD risk factors. RESULTS: A 25% reduction in CVD mortality between 2012 and 2025 achieved through decreased incidence could contain the pace of healthcare cost growth towards 2050 by nearly 7 percentage points for consultations with a physician, and by almost 9 percentage points for hospitalizations. Over the 2012–2050 period, the present value of cost savings is projected to amount to C$13.1 billion in 2012 dollars. The years of life saved due to improved life expectancy could be worth another C$38.2 billion. Addressing CVD mortality directly instead would bring about higher healthcare costs, but would generate more value in terms of years of life saved, at C$69.6 billion. CONCLUSIONS: Potential savings associated with plausible reductions in CVD, aimed at reaching a World Health Organization target over a 12-year period, are sizeable and may help address challenges associated with an aging population. |
format | Online Article Text |
id | pubmed-5754059 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-57540592018-01-26 The economic benefits of reducing cardiovascular disease mortality in Quebec, Canada Boisclair, David Décarie, Yann Laliberté-Auger, François Michaud, Pierre-Carl Vincent, Carole PLoS One Research Article OBJECTIVES: We assess how different scenarios of cardiovascular disease (CVD) prevention, aimed at meeting targets set by the World Health Organization (WHO) for 2025), may impact healthcare spending in Quebec, Canada over the 2050 horizon. METHODS: We provide long-term forecasts of healthcare use and costs at the Quebec population level using a novel dynamic microsimulation model. Using both survey and administrative data, we simulate the evolution of the Quebec population’s health status until death, through a series of dynamic transitions that accounts for social and demographic characteristics associated with CVD risk factors. RESULTS: A 25% reduction in CVD mortality between 2012 and 2025 achieved through decreased incidence could contain the pace of healthcare cost growth towards 2050 by nearly 7 percentage points for consultations with a physician, and by almost 9 percentage points for hospitalizations. Over the 2012–2050 period, the present value of cost savings is projected to amount to C$13.1 billion in 2012 dollars. The years of life saved due to improved life expectancy could be worth another C$38.2 billion. Addressing CVD mortality directly instead would bring about higher healthcare costs, but would generate more value in terms of years of life saved, at C$69.6 billion. CONCLUSIONS: Potential savings associated with plausible reductions in CVD, aimed at reaching a World Health Organization target over a 12-year period, are sizeable and may help address challenges associated with an aging population. Public Library of Science 2018-01-04 /pmc/articles/PMC5754059/ /pubmed/29300783 http://dx.doi.org/10.1371/journal.pone.0190538 Text en © 2018 Boisclair et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Boisclair, David Décarie, Yann Laliberté-Auger, François Michaud, Pierre-Carl Vincent, Carole The economic benefits of reducing cardiovascular disease mortality in Quebec, Canada |
title | The economic benefits of reducing cardiovascular disease mortality in Quebec, Canada |
title_full | The economic benefits of reducing cardiovascular disease mortality in Quebec, Canada |
title_fullStr | The economic benefits of reducing cardiovascular disease mortality in Quebec, Canada |
title_full_unstemmed | The economic benefits of reducing cardiovascular disease mortality in Quebec, Canada |
title_short | The economic benefits of reducing cardiovascular disease mortality in Quebec, Canada |
title_sort | economic benefits of reducing cardiovascular disease mortality in quebec, canada |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5754059/ https://www.ncbi.nlm.nih.gov/pubmed/29300783 http://dx.doi.org/10.1371/journal.pone.0190538 |
work_keys_str_mv | AT boisclairdavid theeconomicbenefitsofreducingcardiovasculardiseasemortalityinquebeccanada AT decarieyann theeconomicbenefitsofreducingcardiovasculardiseasemortalityinquebeccanada AT laliberteaugerfrancois theeconomicbenefitsofreducingcardiovasculardiseasemortalityinquebeccanada AT michaudpierrecarl theeconomicbenefitsofreducingcardiovasculardiseasemortalityinquebeccanada AT vincentcarole theeconomicbenefitsofreducingcardiovasculardiseasemortalityinquebeccanada AT boisclairdavid economicbenefitsofreducingcardiovasculardiseasemortalityinquebeccanada AT decarieyann economicbenefitsofreducingcardiovasculardiseasemortalityinquebeccanada AT laliberteaugerfrancois economicbenefitsofreducingcardiovasculardiseasemortalityinquebeccanada AT michaudpierrecarl economicbenefitsofreducingcardiovasculardiseasemortalityinquebeccanada AT vincentcarole economicbenefitsofreducingcardiovasculardiseasemortalityinquebeccanada |